In this article, we will take a look at the 10 Most Profitable Biotech Stocks to Buy Now.
Following a turbulent year for the markets in general and biotech in particular, the industry made a notable recovery, surpassing both the S&P 500 and the broader market index, and ending 2025 with its highest yearly gains since the Covid-19 pandemic. Meanwhile, a combination of increased visibility and solid market performance has led to a more favorable climate.
Speaking to Investing News Network, Eric Shrayer, director of research at Reynders, McVeigh Capital Management, stated that the most notable development for the life science and biotech sectors in 2025 so far has been the $47 billion NIH budget. According to Shrayer, raising funds is often the most difficult barrier for small biotech companies, especially in a low-growth environment characterized by higher interest rates and stricter capital markets.
In another vein, biotech stocks have seen an increase in M&A activity. In March alone, there were ten acquisitions valued at around $31.5 billion. The approaching patent cliff, which some predict could cost the industry $300 billion by 2030, appears to be a major driver of this activity.
Our Methodology
For this list, we used stock screeners to identify profitable biotechnology stocks with the highest TTM net income and net income margins. These stocks are widely held by hedge funds and followed by analysts.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
10. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) ranks among the most profitable biotech stocks to buy now. On March 25, BofA Securities raised ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Buy from Neutral, retaining a $29 price objective. The firm stated that the nearly 25% drop in the share price recently was due to year-to-date macroeconomic factors rather than fundamentals.
The firm stated that consistent Nuplazid sales in Parkinson’s psychosis give protection against future decline. BofA Securities estimates $888 million in peak sales in 2029, which may be modest, given recent field force investments that could boost growth.
According to BofA Securities, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) estimates that its pipeline has a $11 billion opportunity, which is currently discounted and may offer upside. The firm added that phase 2 data for remlifanserin in Alzheimer’s psychosis is anticipated in August–October and is partially de-risked based on previous Nuplazid psychosis basket trial results. The firm forecasts $2.1 billion in nominal peak sales for 2038, with a 40% chance of success in Alzheimer’s psychosis.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders. It targets unmet medical needs in areas such as Parkinson’s disease, psychosis, schizophrenia, and rare neurological conditions.
9. Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the most profitable biotech stocks to buy now. On April 13, TD Cowen reaffirmed its Buy rating and $96 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). The firm forecasts Halozyme to continue to outperform expectations and enhance guidance due to strong growth catalysts such as Vyvgart Hytrulo, Darzalex Faspro, and Phesgo.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) began to disclose the royalties from these three medications during the past quarter. TD Cowen stated that Vyvgart Hytrulo is a more significant contributor than previously assumed, which reduces the risk of near-term royalty increase, assuming the ongoing success across numerous indications.
Similarly, following a collaboration announcement, Leerink Partners reiterated its Market Perform stock rating and $83 price target for Halozyme Therapeutics, Inc. (NASDAQ:HALO). Halozyme has established an affiliation with Vertex Pharmaceuticals on the Hypercon technology platform.
Compared with Halozyme’s ENHANZE platform, the Hypercon technology enables higher drug concentrations, making at-home treatment possible. In addition to possible future milestone payments and royalties, Vertex will reimburse Halozyme $15 million in advance.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that creates, manufactures, and sells drug-device combination solutions using advanced auto-injector technologies.
8. Argenx SE (NASDAQ:ARGX)
Argenx SE (NASDAQ:ARGX) ranks among the most profitable biotech stocks to buy now. On April 14, TD Cowen maintained its Buy rating and $1,146 price target for Argenx SE (NASDAQ:ARGX), citing a quarterly monitoring poll that indicated first-quarter sales could outperform consensus projections. The firm’s fifth quarterly study of 30 neurologists treating patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy revealed persistent interest in the Vyvgart brand.
According to TD Cowen, Vyvgart’s first-quarter revenues will exceed the consensus expectation of $1,271 million, which is a 1% decrease from the previous quarter. The firm ascribed the predicted increase to the adoption of the Vyvgart Hytrulo prefilled syringe formulation.
According to the aforesaid study, the prefilled syringe formulation, which is still being used in both generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy diagnosis, was notably favored.
TD Cowen also voiced optimism about possible launches in ocular myasthenia gravis, for which a submission is expected shortly, and seronegative myasthenia gravis, which has a regulatory judgment date of May 10.
Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.
7. Incyte Corporation (NASDAQ:INCY)
Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation (NASDAQ:INCY)’s Buy rating and $135 price target. The firm stated that Incyte’s povorcitinib could be administered in the early stages of hidradenitis suppurativa, rather than as a post-biologic oral alternative.
H.C. Wainwright mentioned a meeting with a hidradenitis suppurativa expert who oversees a clinic at Geisinger Health with about 700 patients rotating each year, with nearly 80% categorized as moderate to severe.
In a similar vein, Citizens JMP reaffirmed its Market Perform rating for Incyte Corporation (NASDAQ:INCY) following the presentation of revised clinical trial data at the AAD 2026 Congress. Incyte reported 54-week results from the Phase 3 STOP-HS1/HS2 studies, which evaluated povorcitinib in moderate-to-severe hidradenitis suppurativa.
The data demonstrated that effectiveness deepens gradually with increasing HiSCR50 rates in both the initial treatment and crossover groups. Citizens stated that it has grown more convinced that implementation across the current portfolio can overcome the $3 billion-plus ruxolitinib patent gap by the end of 2028.
Incyte Corporation (NASDAQ:INCY), an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer.
6. Genmab A/S (NASDAQ:GMAB)
Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to buy now. Wolfe Research began coverage of Genmab A/S (NASDAQ:GMAB) on March 26 with a price objective of $32 and an Outperform rating. In anticipation of clinical triggers anticipated in 2026, the firm sees the current price dip following a loss in a confirmatory DLBCL study as a purchasing opportunity.
According to the firm, Genmab’s Epkinly is expected to bring in $3.4 billion in peak sales, with the frontline trial EPCORE DLBCL-2 being the main value engine for the asset. Similarly, Rina-S could generate $2.5 billion in peak sales spanning many indications, with Wolfe anticipating findings from the RAINFOL-01 PROC this year.
Also, with regard to sales, Genmab A/S (NASDAQ:GMAB) reported that DARZALEX’s global net sales amounted to $3.964 billion in Q1 2026. The sales data include cancer treatment formulas administered intravenously and subcutaneously. Net sales in the US totaled $2.208 billion, with international markets generating $1.756 billion in revenue.
Genmab A/S (NASDAQ:GMAB) is a biotechnology company specializing in oncology, developing innovative antibody-based therapies for cancer treatment. Its late-stage pipeline includes promising programs like Rina‑S and EPKINLY.
While we acknowledge the potential of GMAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GMAB and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Most Profitable Biotech Stocks to Buy Now.
Disclosure: None. Follow Insider Monkey on Google News.
